ArticleHereditas2026
miR-4513 promotes the proliferation and metastasis of non-small cell lung cancer cells by targeting VIPR1.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe pathogenesis of non-small cell lung cancer (NSCLC) is complex. This research focuses on the expression, function, and molecular mechanisms of miR-4513 in NSCLC.
methodA total of 126 matched tissue pairs (NSCLC and adjacent normal) were collected, along with assessment of miR-4513 and VIPR1 expression in multiple cell lines (A549, H1299, BEAS-2B) by qRT-PCR. In vitro, the influence of miR-4513 on cellular phenotypes was assessed by determining proliferation rates through CCK-8 assay and quantifying migration/invasion capacities via Transwell systems. Targetscan predicted the targeting relationship between miR-4513 and VIPR1, which was subsequently confirmed by dual-luciferase.
resultsThe expression of miR-4513 is upregulated in NSCLC tissues. The high expression of miR-4513 is associated with pathological features. Survival analysis revealed that high expression of miR-4513 was an independent predictor of unfavorable clinical outcomes in NSCLC patients. In vitro, overexpression of miR-4513 can promote the proliferation, migration and invasion of NSCLC cells, while inhibition of its expression has the opposite effect. VIPR1 overexpression significantly inhibited the proliferation and invasion of NSCLC cells, confirming its tumor-suppressive role. Furthermore, miR-4513 can directly bind to the 3'UTR region of the VIPR1 gene and show a negative correlation with it.
conclusionsHigh expression of miR-4513 may serve as a potential biomarker for poor prognosis in NSCLC patients. In addition, miR-4513 may promote the malignant progression of NSCLC by targeting VIPR1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.